MET and non-small cell lung carcinoma: The combined HR for the nine studies [13], [14], [18]–[20], [21], [23], [24], [34] (involving 2151 cases) included in the univariate analysis was 1.52 (95% CI: 1.08–2.15, p = 0.0017), indicating that MET overexpression had worse survival impact in patients with NSCLC (Figure 5).